SG10202106949XA - Pyrrolopyrimidines as cftr potentiators - Google Patents
Pyrrolopyrimidines as cftr potentiatorsInfo
- Publication number
- SG10202106949XA SG10202106949XA SG10202106949XA SG10202106949XA SG10202106949XA SG 10202106949X A SG10202106949X A SG 10202106949XA SG 10202106949X A SG10202106949X A SG 10202106949XA SG 10202106949X A SG10202106949X A SG 10202106949XA SG 10202106949X A SG10202106949X A SG 10202106949XA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrrolopyrimidines
- cftr potentiators
- potentiators
- cftr
- Prior art date
Links
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423919P | 2016-11-18 | 2016-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202106949XA true SG10202106949XA (en) | 2021-07-29 |
Family
ID=62144793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202106949XA SG10202106949XA (en) | 2016-11-18 | 2017-11-17 | Pyrrolopyrimidines as cftr potentiators |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10301315B2 (en) |
| EP (1) | EP3541390B1 (en) |
| JP (3) | JP6978507B2 (en) |
| KR (2) | KR20230146104A (en) |
| CN (2) | CN115850268A (en) |
| AU (2) | AU2017362350B2 (en) |
| BR (1) | BR112019010167A2 (en) |
| CA (1) | CA3044050A1 (en) |
| CL (1) | CL2019001334A1 (en) |
| CO (1) | CO2019005993A2 (en) |
| CR (1) | CR20190292A (en) |
| DO (1) | DOP2019000126A (en) |
| EC (1) | ECSP19043120A (en) |
| IL (2) | IL296279A (en) |
| MX (2) | MX2021012639A (en) |
| PE (1) | PE20200739A1 (en) |
| PH (1) | PH12019501098A1 (en) |
| RU (2) | RU2757457C2 (en) |
| SG (1) | SG10202106949XA (en) |
| UA (1) | UA125400C2 (en) |
| WO (1) | WO2018094137A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9487495B2 (en) | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| EP4159717A1 (en) | 2014-10-06 | 2023-04-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2017112853A1 (en) * | 2015-12-22 | 2017-06-29 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
| US10570115B2 (en) | 2016-09-30 | 2020-02-25 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN115850268A (en) * | 2016-11-18 | 2023-03-28 | 囊性纤维化基金会 | Pyrrolopyrimidines as CFTR potentiators |
| RS61150B1 (en) | 2016-12-09 | 2020-12-31 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| SG10201911076QA (en) | 2016-12-16 | 2020-01-30 | Cystic Fibrosis Found | Bycyclic heteroaryl derivatives as cftr potentiators |
| CA3066084A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AR112467A1 (en) | 2017-08-02 | 2019-10-30 | Vertex Pharma | PROCESSES FOR PREPARING COMPOUNDS |
| EP3697774A1 (en) | 2017-10-19 | 2020-08-26 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| AU2018380426B2 (en) | 2017-12-08 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (en) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | Pharmaceutical compositions for treating cystic fibrosis |
| RS64018B1 (en) | 2018-02-15 | 2023-03-31 | Vertex Pharma | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| US20200383960A1 (en) * | 2019-06-10 | 2020-12-10 | Novartis Ag | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis |
| WO2021009695A1 (en) | 2019-07-15 | 2021-01-21 | Novartis Ag | Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide |
| TW202120517A (en) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | Process of making cftr modulators |
| EP4013760A1 (en) | 2019-08-14 | 2022-06-22 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TW202115092A (en) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN111138439B (en) * | 2020-01-17 | 2021-06-25 | 厦门大学 | Fluoro pyrrolopyrimidine compound and preparation method and application thereof |
| EP4114837A1 (en) | 2020-03-06 | 2023-01-11 | Bayer Aktiengesellschaft | Pyrazolopyrazines acting on cancers via inhibition of cdk12 |
| AU2021329507A1 (en) | 2020-08-20 | 2023-03-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating respiratory diseases characterized by mucus hypersecretion |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0674641T3 (en) * | 1992-12-17 | 1999-09-27 | Pfizer | Pyrrolopyrimidines as CRF antagonists |
| NZ518726A (en) * | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US20030187007A1 (en) * | 2001-05-30 | 2003-10-02 | Cao Sheldon Xiaodong | Inhibitors of protein kinase for the treatment of disease |
| WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| WO2005074603A2 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| US7772231B2 (en) * | 2005-12-29 | 2010-08-10 | Abbott Laboratories | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors |
| WO2007104944A1 (en) * | 2006-03-11 | 2007-09-20 | Vernalis (R & D) Ltd. | Pyrrolopyrimidine derivatives used as hsp90 inhibitors |
| KR20150038395A (en) * | 2006-04-04 | 2015-04-08 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | Kinase antagonists |
| EP2217239A2 (en) * | 2007-11-07 | 2010-08-18 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| ME02230B (en) * | 2009-01-08 | 2016-02-20 | Curis Inc | Phosphoinositide 3 - kinase inhibitors with a zinc binding moiety |
| WO2013071232A1 (en) | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules |
| US8828998B2 (en) * | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014060431A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| WO2015091532A1 (en) | 2013-12-19 | 2015-06-25 | Almirall, S.A. | Pyrrolopyrimidine derivatives as pi3k inhibitors |
| CN115850268A (en) * | 2016-11-18 | 2023-03-28 | 囊性纤维化基金会 | Pyrrolopyrimidines as CFTR potentiators |
-
2017
- 2017-11-17 CN CN202211239693.0A patent/CN115850268A/en active Pending
- 2017-11-17 BR BR112019010167A patent/BR112019010167A2/en active Search and Examination
- 2017-11-17 KR KR1020237033420A patent/KR20230146104A/en active Application Filing
- 2017-11-17 RU RU2019118623A patent/RU2757457C2/en active
- 2017-11-17 JP JP2019547579A patent/JP6978507B2/en active Active
- 2017-11-17 IL IL296279A patent/IL296279A/en unknown
- 2017-11-17 WO PCT/US2017/062148 patent/WO2018094137A1/en active Application Filing
- 2017-11-17 UA UAA201906838A patent/UA125400C2/en unknown
- 2017-11-17 SG SG10202106949XA patent/SG10202106949XA/en unknown
- 2017-11-17 EP EP17872726.9A patent/EP3541390B1/en active Active
- 2017-11-17 CN CN201780083801.0A patent/CN110337294B/en active Active
- 2017-11-17 US US15/815,809 patent/US10301315B2/en active Active
- 2017-11-17 CA CA3044050A patent/CA3044050A1/en active Pending
- 2017-11-17 MX MX2021012639A patent/MX2021012639A/en unknown
- 2017-11-17 PE PE2019001045A patent/PE20200739A1/en unknown
- 2017-11-17 RU RU2021129721A patent/RU2021129721A/en unknown
- 2017-11-17 MX MX2019005822A patent/MX2019005822A/en unknown
- 2017-11-17 CR CR20190292A patent/CR20190292A/en unknown
- 2017-11-17 AU AU2017362350A patent/AU2017362350B2/en active Active
- 2017-11-17 KR KR1020197017510A patent/KR102585398B1/en active IP Right Grant
-
2019
- 2019-04-05 US US16/377,005 patent/US10494374B2/en active Active
- 2019-05-15 IL IL266668A patent/IL266668B2/en unknown
- 2019-05-16 PH PH12019501098A patent/PH12019501098A1/en unknown
- 2019-05-16 CL CL2019001334A patent/CL2019001334A1/en unknown
- 2019-05-17 DO DO2019000126A patent/DOP2019000126A/en unknown
- 2019-06-07 CO CONC2019/0005993A patent/CO2019005993A2/en unknown
- 2019-06-17 EC ECSENADI201943120A patent/ECSP19043120A/en unknown
- 2019-09-20 US US16/578,277 patent/US20200017512A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/179,062 patent/US20210171534A1/en not_active Abandoned
- 2021-11-10 JP JP2021183048A patent/JP7360434B2/en active Active
-
2022
- 2022-03-16 AU AU2022201816A patent/AU2022201816B2/en active Active
-
2023
- 2023-04-13 US US18/134,455 patent/US20230250100A1/en active Pending
- 2023-09-29 JP JP2023169299A patent/JP2023182694A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266668A (en) | Pyrrolopyrimidines as cftr potentiators | |
| SG10201911221RA (en) | Bicyclic heteroaryl derivatives as cftr potentiators | |
| IL252135A0 (en) | Triazolopyrimidine compounds and uses thereof | |
| AU201614646S (en) | Pitch-propelled vehicle | |
| GB2573382B (en) | Vehicle | |
| HK1244744B (en) | Ride | |
| PL3203592T3 (en) | Socket | |
| GB201615693D0 (en) | Combinations | |
| HRP20190111T1 (en) | Snow-removal trailer | |
| EP3558864A4 (en) | Nanoparticles | |
| HK1258473A1 (en) | Deuterated cftr potentiators | |
| GB201602188D0 (en) | Coalescents | |
| EP3551231A4 (en) | Bismuth-gadolinium nanoparticles | |
| GB201619615D0 (en) | Transformable vehicle | |
| GB201617377D0 (en) | Trailer | |
| PL3330116T3 (en) | Vehicle | |
| GB2551105B (en) | Vehicle | |
| AU2016905306A0 (en) | Nanoparticles | |
| GB201617995D0 (en) | Vehicles etc | |
| GB201615720D0 (en) | Vehicle | |
| GB201615722D0 (en) | Vehicle | |
| AU201614599S (en) | Vehicle | |
| AP00905S1 (en) | Vehicle | |
| AP00896S1 (en) | Vehicle | |
| TWM534499U (en) | Anti-disassembling chassis |